|
Mr. Schmitt is responsible for development and execution of commercial strategies for Immtech’s pipeline of products. Mr. Schmitt has over 17 years of product planning and business development experience, having held similar positions in both large pharmaceutical and small biotechnology companies. Most recently, Mr. Schmitt was at First Genetic Trust (FGT), where he served as Director of Academic Partnerships. Prior to joining FGT, Mr. Schmitt was Director of Global Oncology at Searle/Pharmacia, where he headed the commercial teams responsible for developing strategies for Searle’s anti-angiogenesis and immunotherapy programs. During his career, Daniel has led and contributed to the successful development and launch of over 12 pharmaceutical products, including 5 new chemical entities. Mr. Schmitt received his M.B.A and a B.S. in Chemistry from West Virginia University and has held research positions affiliated with the National Foundation for Cancer Research and at the University of North Carolina, School of Medicine. | 